Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 2
1978 4
1979 10
1980 7
1981 7
1982 16
1983 25
1984 13
1985 15
1986 18
1987 24
1988 12
1989 33
1990 29
1991 27
1992 30
1993 26
1994 18
1995 33
1996 20
1997 25
1998 28
1999 36
2000 30
2001 24
2002 52
2003 37
2004 46
2005 41
2006 34
2007 38
2008 22
2009 31
2010 45
2011 48
2012 38
2013 45
2014 50
2015 43
2016 36
2017 32
2018 27
2019 25
2020 36
2021 41
2022 25
2023 30
2024 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,234 results

Results by year

Filters applied: . Clear all
Page 1
Levonorgestrel vs. Copper Intrauterine Devices for Emergency Contraception.
Turok DK, Gero A, Simmons RG, Kaiser JE, Stoddard GJ, Sexsmith CD, Gawron LM, Sanders JN. Turok DK, et al. N Engl J Med. 2021 Jan 28;384(4):335-344. doi: 10.1056/NEJMoa2022141. N Engl J Med. 2021. PMID: 33503342 Free PMC article. Clinical Trial.
BACKGROUND: In the United States, more intrauterine device (IUD) users select levonorgestrel IUDs than copper IUDs for long-term contraception. Currently, clinicians offer only copper IUDs for emergency contraception because data are lacking on the efficacy of the levon …
BACKGROUND: In the United States, more intrauterine device (IUD) users select levonorgestrel IUDs than copper IUDs for long-term cont …
Control of endometriosis-associated pain with etonogestrel-releasing contraceptive implant and 52-mg levonorgestrel-releasing intrauterine system: randomized clinical trial.
Carvalho N, Margatho D, Cursino K, Benetti-Pinto CL, Bahamondes L. Carvalho N, et al. Fertil Steril. 2018 Nov;110(6):1129-1136. doi: 10.1016/j.fertnstert.2018.07.003. Fertil Steril. 2018. PMID: 30396557 Free article. Clinical Trial.
OBJECTIVE: To assess the efficacy of an etonogestrel (ENG)-releasing contraceptive implant or the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS) in the control of endometriosis-associated pelvic pain. ...
OBJECTIVE: To assess the efficacy of an etonogestrel (ENG)-releasing contraceptive implant or the 52-mg levonorgestrel-releasing intr …
Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis.
Glasier AF, Cameron ST, Fine PM, Logan SJ, Casale W, Van Horn J, Sogor L, Blithe DL, Scherrer B, Mathe H, Jaspart A, Ulmann A, Gainer E. Glasier AF, et al. Lancet. 2010 Feb 13;375(9714):555-62. doi: 10.1016/S0140-6736(10)60101-8. Epub 2010 Jan 29. Lancet. 2010. PMID: 20116841 Clinical Trial.
There were 15 pregnancies in the ulipristal acetate group (1.8%, 95% CI 1.0-3.0) and 22 in the levonorgestrel group (2.6%, 1.7-3.9; odds ratio [OR] 0.68, 95% CI 0.35-1.31). In 203 women who received emergency contraception between 72 h and 120 h after sexual intercourse, t …
There were 15 pregnancies in the ulipristal acetate group (1.8%, 95% CI 1.0-3.0) and 22 in the levonorgestrel group (2.6%, 1.7-3.9; o …
Oral emergency contraception with levonorgestrel plus piroxicam: a randomised double-blind placebo-controlled trial.
Li RHW, Lo SST, Gemzell-Danielsson K, Fong CHY, Ho PC, Ng EHY. Li RHW, et al. Lancet. 2023 Sep 9;402(10405):851-858. doi: 10.1016/S0140-6736(23)01240-0. Epub 2023 Aug 16. Lancet. 2023. PMID: 37597523 Clinical Trial.
Women who required levonorgestrel EC within 72 h of unprotected sexual intercourse were recruited and block-randomised in a 1:1 ratio to receive a single supervised dose of levonorgestrel 1.5 mg plus either piroxicam 40 mg or placebo orally. ...INTERPRETATION: Oral …
Women who required levonorgestrel EC within 72 h of unprotected sexual intercourse were recruited and block-randomised in a 1:1 ratio …
Efficacy, safety, and tolerability of a levonorgestrel/ethinyl estradiol transdermal delivery system: Phase 3 clinical trial results.
Nelson AL, Kaunitz AM, Kroll R, Simon JA, Poindexter AN, Castaño PM, Ackerman RT, Flood L, Chiodo JA 3rd, Garner EI; SECURE Investigators. Nelson AL, et al. Contraception. 2021 Mar;103(3):137-143. doi: 10.1016/j.contraception.2020.11.011. Epub 2020 Nov 28. Contraception. 2021. PMID: 33259782 Free article. Clinical Trial.
OBJECTIVE: To assess the contraceptive efficacy, safety, and tolerability of a contraceptive transdermal delivery system, (TDS; TWIRLA(R)) containing levonorgestrel (LNG) and ethinyl estradiol (EE). STUDY DESIGN: This single-arm, open-label, multicenter, 1-year (13 cycle), …
OBJECTIVE: To assess the contraceptive efficacy, safety, and tolerability of a contraceptive transdermal delivery system, (TDS; TWIRLA(R)) c …
A multicenter randomized clinical trial of etonogestrel and levonorgestrel contraceptive implants with nonrandomized copper intrauterine device controls: effect on weight variations up to 3 years after placement.
Bahamondes L, Brache V, Ali M, Habib N; WHO study group on contraceptive implants for women. Bahamondes L, et al. Contraception. 2018 Sep;98(3):181-187. doi: 10.1016/j.contraception.2018.05.009. Epub 2018 May 16. Contraception. 2018. PMID: 29777663 Clinical Trial.
OBJECTIVES: To evaluate weight changes in women randomized to either the etonogestrel (ENG)- or the levonorgestrel (LNG)-releasing contraceptive implants and to compare with users of the TCu380A intrauterine device (IUD). ...
OBJECTIVES: To evaluate weight changes in women randomized to either the etonogestrel (ENG)- or the levonorgestrel (LNG)-releasing co …
Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial.
Kaunitz AM, Portman D, Westhoff CL, Archer DF, Mishell DR Jr, Rubin A, Foegh M. Kaunitz AM, et al. Obstet Gynecol. 2014 Feb;123(2 Pt 1):295-303. doi: 10.1097/AOG.0000000000000095. Obstet Gynecol. 2014. PMID: 24402597 Clinical Trial.
OBJECTIVE: To compare a new low-dose levonorgestrel and ethinyl estradiol contraceptive patch (Patch) with a combination oral contraceptive (Pill; 100 micrograms levonorgestrel, 20 micrograms ethinyl estradiol) regarding efficacy, safety, compliance, and unscheduled …
OBJECTIVE: To compare a new low-dose levonorgestrel and ethinyl estradiol contraceptive patch (Patch) with a combination oral contrac …
Anastrozole and levonorgrestrel-releasing intrauterine device in the treatment of endometriosis: a randomized clinical trial.
Acién P, Velasco I, Acién M. Acién P, et al. BMC Womens Health. 2021 May 20;21(1):211. doi: 10.1186/s12905-021-01347-9. BMC Womens Health. 2021. PMID: 34016111 Free PMC article. Clinical Trial.
BACKGROUND: To study the effectiveness of an aromatase inhibitor (Anastrozole) associated with levonorgestrel-releasing intrauterine device (LNG-IUD, Mirena) in the treatment of endometriosis. ...
BACKGROUND: To study the effectiveness of an aromatase inhibitor (Anastrozole) associated with levonorgestrel-releasing intrauterine …
A Randomized Clinical Trial of Levonorgestrel Intrauterine System with or without Metformin for Treatment of Endometrial Hyperplasia without Atypia in Indian Women.
Ravi RD, Kalra J, Srinivasan R, Bagga R, Jain V, Suri V, Sachdeva N. Ravi RD, et al. Asian Pac J Cancer Prev. 2021 Mar 1;22(3):983-989. doi: 10.31557/APJCP.2021.22.3.983. Asian Pac J Cancer Prev. 2021. PMID: 33773565 Free PMC article. Clinical Trial.
Twenty-five subjects were prescribed metformin 500mg twice daily with Levonorgestrel intrauterine system and 26 subjects, with Levonorgestrel intrauterine system only for 6 months. ...RESULTS: Clinical response was observed in 23 of 25 subjects in metformin group an …
Twenty-five subjects were prescribed metformin 500mg twice daily with Levonorgestrel intrauterine system and 26 subjects, with Lev …
Heavy Menstrual Bleeding Treatment With a Levonorgestrel 52-mg Intrauterine Device.
Creinin MD, Barnhart KT, Gawron LM, Eisenberg D, Mabey RG Jr, Jensen JT. Creinin MD, et al. Obstet Gynecol. 2023 May 1;141(5):971-978. doi: 10.1097/AOG.0000000000005137. Epub 2023 Apr 5. Obstet Gynecol. 2023. PMID: 37023455 Free PMC article. Clinical Trial.
OBJECTIVE: To evaluate heavy menstrual bleeding treatment outcomes with levonorgestrel 52-mg intrauterine device (IUD) use in participants without body mass index (BMI) or parity restrictions. ...The most common adverse events leading to discontinuation were bleeding or cr …
OBJECTIVE: To evaluate heavy menstrual bleeding treatment outcomes with levonorgestrel 52-mg intrauterine device (IUD) use in partici …
1,234 results